The effect of fine-particle size and extrafine particle size inhaled corticosteroid in reducing airway resistance in asthmatic patients

IF 0.4 Q3 MEDICINE, GENERAL & INTERNAL
Mohamed Faisal Abdul Hamid, Asyraf Ahmad, Mas Fazlin Mohamad Jailaini, Shahrul Aiman Soelar, Nik Nuratiqah Nik Abeed, Ng Boon Hau, Azat Azrai Azmel, Andrea Ban
{"title":"The effect of fine-particle size and extrafine particle size inhaled corticosteroid in reducing airway resistance in asthmatic patients","authors":"Mohamed Faisal Abdul Hamid, Asyraf Ahmad, Mas Fazlin Mohamad Jailaini, Shahrul Aiman Soelar, Nik Nuratiqah Nik Abeed, Ng Boon Hau, Azat Azrai Azmel, Andrea Ban","doi":"10.1177/20101058231167250","DOIUrl":null,"url":null,"abstract":"Background Bronchial asthma is characterised by chronic inflammation of both large and small airways. Extra-fine formulation of inhaled corticosteroid (ICS) can achieve a higher peripheral lung deposition leading to improved asthma control. We investigated the effect of extra-fine and fine particle size inhaled ICS with airway resistance and severity of symptoms in asthmatic patients. Methods Prospective interventional study of outpatient asthmatics in Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Subjects were grouped based on pre-existing inhalers; extra-fine and fine inhaled corticosteroid (ICS)/long acting beta agonist (LABA). Crossover was at week 7 and treatment regime continued for 7 weeks. Subjects were assessed at week 0, 6 and 13 using asthma control test (ACT) score, forced expiratory volume in 1 s (FEV 1 ) and impulse oscillometry (IOS) Inhaler technique was assessed periodically. Results Thirty-four subjects were recruited. Median asthma duration was 20 years. Twenty subjects (58%) in fine ICS/LABA and 14 (42%) in extra-fine ICS/LABA group. Thirty-one subjects were analysed before crossver. There was a significant improvement of FEV 1 in the extra-fine ICS/LABA group (1.7 ± 0.47 to 1.88 ± 0.5; p = 0.01). ACT score reduced significantly in extra-fine ICS/LABA group (23 ± 5 to 21 ± 4; p = 0.04) at week 0–6. Week 7–13 showed a significant improvement of ACT score (16.5 ± 3 to 20 ± 3; p = 0.01) and FEV1 (1.71 ± 0.96 to 1.81 ± 1.02: p = 0.01) in extra-fine ICS/LABA. There was no significant difference in (IOS) parameters between the groups. Conclusion There was an improvement of FEV 1 and ACT score with extra-fine ICS/LABA with no benefit in airway resistance.","PeriodicalId":44685,"journal":{"name":"Proceedings of Singapore Healthcare","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Singapore Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20101058231167250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background Bronchial asthma is characterised by chronic inflammation of both large and small airways. Extra-fine formulation of inhaled corticosteroid (ICS) can achieve a higher peripheral lung deposition leading to improved asthma control. We investigated the effect of extra-fine and fine particle size inhaled ICS with airway resistance and severity of symptoms in asthmatic patients. Methods Prospective interventional study of outpatient asthmatics in Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Subjects were grouped based on pre-existing inhalers; extra-fine and fine inhaled corticosteroid (ICS)/long acting beta agonist (LABA). Crossover was at week 7 and treatment regime continued for 7 weeks. Subjects were assessed at week 0, 6 and 13 using asthma control test (ACT) score, forced expiratory volume in 1 s (FEV 1 ) and impulse oscillometry (IOS) Inhaler technique was assessed periodically. Results Thirty-four subjects were recruited. Median asthma duration was 20 years. Twenty subjects (58%) in fine ICS/LABA and 14 (42%) in extra-fine ICS/LABA group. Thirty-one subjects were analysed before crossver. There was a significant improvement of FEV 1 in the extra-fine ICS/LABA group (1.7 ± 0.47 to 1.88 ± 0.5; p = 0.01). ACT score reduced significantly in extra-fine ICS/LABA group (23 ± 5 to 21 ± 4; p = 0.04) at week 0–6. Week 7–13 showed a significant improvement of ACT score (16.5 ± 3 to 20 ± 3; p = 0.01) and FEV1 (1.71 ± 0.96 to 1.81 ± 1.02: p = 0.01) in extra-fine ICS/LABA. There was no significant difference in (IOS) parameters between the groups. Conclusion There was an improvement of FEV 1 and ACT score with extra-fine ICS/LABA with no benefit in airway resistance.
细颗粒和细颗粒吸入皮质类固醇对降低哮喘患者气道阻力的影响
支气管哮喘的特点是大气道和小气道的慢性炎症。吸入皮质类固醇(ICS)的超精细配方可以实现更高的外周肺沉积,从而改善哮喘控制。我们探讨超细和细颗粒吸入ICS对哮喘患者气道阻力和症状严重程度的影响。方法对马来西亚Kebangsaan大学医学中心门诊哮喘患者进行前瞻性介入研究。受试者根据已有吸入器进行分组;超细和细吸入皮质类固醇(ICS)/长效受体激动剂(LABA)。在第7周进行交叉,治疗方案持续7周。于第0、6和13周采用哮喘控制试验(ACT)评分、1 s用力呼气量(FEV 1)和脉冲振荡法(IOS)定期评估受试者吸入器技术。结果共招募34名受试者。中位哮喘持续时间为20年。细ICS/LABA组20例(58%),超细ICS/LABA组14例(42%)。31名受试者在交叉前进行了分析。超细ICS/LABA组FEV 1明显改善(1.7±0.47 ~ 1.88±0.5);P = 0.01)。超微ICS/LABA组ACT评分明显降低(23±5 ~ 21±4);P = 0.04)。第7-13周ACT评分显著提高(16.5±3 ~ 20±3);p = 0.01)和FEV1(1.71±0.96 ~ 1.81±1.02:p = 0.01)。两组间(IOS)参数差异无统计学意义。结论超细ICS/LABA可改善FEV 1和ACT评分,但对气道阻力无改善作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Proceedings of Singapore Healthcare
Proceedings of Singapore Healthcare MEDICINE, GENERAL & INTERNAL-
CiteScore
0.90
自引率
0.00%
发文量
42
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信